Kimberley Maruncic is an associate in the firm’s Business Law Department and a member of its Technology and Life Science groups. Ms. Maruncic advises clients on a wide range of corporate matters, including company formation, venture capital financings, mergers and acquisitions and general corporate and securities law. She joined Goodwin in 2018.

Ms. Maruncic is admitted to practice in New York and Massachusetts only. She is working under the supervision of the partners at Goodwin.

Areas of Practice
Domaines D’Expertise





Representative Matters



Venture Financings
  • BridgeBio Pharma, LLC and Maze Therapeutics joint venture 
  • Blackstone Life Sciences and Ferring joint venture for over $570 million
  • RA Capital and Versant Ventures on their €66 million Series A Financing in T-Knife 
  • Anthos Therapeutics, LLC in its $250 million Series A Preferred Unit Financing  
  • Anthos Theraputics, Inc. in tis $53 million Series A Financing 
  • ElevateBio LLC in its $170 million Series B Financing and $150 million Series A Financing
  • Kymera Therapeutics, Inc. in its $102 million cross-over Series C Financing 
  • Allovir Inc. in its $120 million Series B Financing 
  • ViraCyte, Inc. in its $121 million Series B Financing 
  • Gemini Therapeutics Inc. in its $50 million Series B Financing
  • Numerous other private companies and venture capital firms in connection with equity and convertible debt financings
M&A and Strategic Transactions
  • AppNexus in its sale to AT&T.
  • Acquia, Inc. in its sale to Vista Equity Partners 
  • Repligen Corporation in its acquisition of Avitide, Inc.
  • Repligen Corporation in its acquisition ARTeSYN Biosolutions Holdings Ireland Limited
  • Repligen Corporation in its acquisition of Engineered Molding Technology LLC
  • HealthEdge Software, Inc. in its sale to Blackstone
  • Sansoro Health, Inc. in its acquisition of Datica, Inc. 
  • Acquia Inc. in its acquisition of Cohesion Web Technologies Limited 
  • Acquia Inc. in its acquisition of Mautic, Inc. 
  • PlumChoice, Inc. in its sale to SquareTrade, Inc., a subsidiary of Allstate Corporation
  • Mevion Medical Systems, Inc. in its sale to Henan Maisheng Medical Technology Co., Ltd
Capital Market Transactions
  • Dynatrace, Inc. in its $862.5 million follow-on offering.
  • Dynatrace, Inc. in its $680 million follow-on offering.
  • Dynatrace, Inc. in its $620 million initial public offering.
Professional Experience

Prior to joining Goodwin, Ms. Maruncic worked as an associate for Davis, Malm & D’Agostine, P.C., Reebok International Ltd. and the Boston Red Sox. Prior to law school, Ms. Maruncic worked as a Client Service Specialist for Gavin Management Group, a management company for professional hockey players.

In The News









J.D., 2016
Northeastern University School of Law
B.A., Mathematics, concentration in Finance, 2009
Wilfrid Laurier University



New York
Profile Image
Get In Touch
Our clients rely on us for world-class advisory services, counsel on complex transactional work and high-stakes litigation. Specializing in matters involving the financial, life sciences, private equity, real estate, and technology industries, we use a collaborative, cross-disciplinary approach to resolve our clients’ most challenging issues. To find out more, please contact us.


Nos équipes interviennent aux côtés de nos clients, industriels, fonds d’investissement, startups, institutions financières et dirigeants, dans le cadre de transactions et de contentieux complexes, et apportent des conseils de tout premier plan dans les secteurs financiers, des Sciences de la Vie, du Private Equity, de l’immobilier et des technologies. Nous traitons les dossiers juridiques de manière intègre, ingénieuse, souple et audacieuse pour répondre efficacement aux enjeux propres à chacun de nos clients, quels que soient la taille de l’opération et le secteur d’activité. Pour en savoir plus, contactez-nous.

Unsere Kunden verlassen sich auf unsere erstklassige Beratung, vor allem im Hinblick auf komplexe Transaktionen und High-Stakes-Prozesse. Spezialisiert auf Angelegenheiten der Finanz-, Life-Sciences-, Private-Equity-, Immobilien-und Technologie-Branchen, verwenden wir einen kooperativen und interdisziplinären Ansatz, um Fragen unserer Kunden auch in extremen Spezialsituationen einer Lösung zuzuführen. Sie wollen mehr erfahren? Kontaktieren Sie uns gerne.